Recruiting EARLY_PHASE1 INTERVENTIONAL 3-arm NCT06326476

An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

An Open-label Parallel Group Pilot Study to Demonstrate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa

Sponsor: ITB-Med LLC

Conditions Hidradenitis Suppurativa

Interventions Siplizumab

Updated 5 times since 2024 Last updated: May 22, 2025 Started: May 9, 2025 Primary completion: Dec 31, 2026 Completion: Jul 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Hidradenitis Suppurativa, this trial is actively recruiting participants. The trial is conducted by ITB-Med LLC and has accumulated 5 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Jun 2025 — Present [monthly]

Recruiting EARLY_PHASE1

Status: Not Yet Recruiting → Recruiting
Feb 2025 — Jun 2025 [monthly]

Not Yet Recruiting EARLY_PHASE1
Sep 2024 — Feb 2025 [monthly]

Not Yet Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1
Apr 2024 — Jul 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ITB-Med LLC
University of Alabama at Birmingham

Data source: University of Alabama at Birmingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Birmingham, United States